Yubo International Biotech Limited
YBGJOTCHealthcare● Active
$0.01
+$0.00(+0.00%)
Market Cap$1006454
P/E Ratio—
52W High$0.1776
52W Low$0.0079
Yubo International Biotech Limited (YBGJ) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · YBGJ · as of 2026-06-15
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.13M | $0.00M | $0.10M | $1.24M | $1.35M |
| Cost of Revenue | $0.13M | $0.21M | $0.05M | $0.42M | $0.11M |
| Gross Profit | $0.01M | ($0.21M) | $0.05M | $0.82M | $1.24M |
| Gross Margin %(computed) | 6.08% | — | 50.49% | 65.95% | 91.56% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $0.88M | $1.25M | $1.04M | $1.31M | $0.54M |
| Total Operating Expenses | $1.20M | $1.56M | $1.26M | $2.36M | $1.95M |
| Operating Income | ($1.19M) | ($1.77M) | ($1.21M) | ($1.54M) | ($0.71M) |
| Operating Margin %(computed) | -883.76% | — | — | -123.99% | -52.58% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | ($0.00M) | $0.00M | $0.00M | $427.00M | $0.00M |
| Income Before Tax | ($1.19M) | ($1.98M) | ($1.20M) | ($1.54M) | ($0.71M) |
| Income Tax Expense | ($0.11M) | ($0.21M) | ($0.00M) | ($0.00M) | $0.00M |
| Net Income | ($1.08M) | ($1.78M) | ($1.20M) | ($1.54M) | ($0.71M) |
| Net Margin %(computed) | -803.07% | — | — | -123.92% | -52.58% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 |
| Wtd Avg Shares | 139.64M | 119.82M | 118.72M | 118.13M | 118.18M |
| EBITDA | ($1.01M) | ($1.80M) | ($1.18M) | ($1.52M) | ($0.70M) |
| EBITDA Margin %(computed) | -751.48% | — | — | -122.27% | -51.61% |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · USD · M
Explore more Yubo International Biotech Limited data
About Yubo International Biotech Limited (YBGJ) Income Statement
Yubo International Biotech Limited (YBGJ) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, YBGJ reported revenue of $0.00B, gross profit of $0.00B (gross margin 6.08%), and net income of ($0.00B) — a net profit margin of -803.07%.
Frequently asked questions
YBGJ · 4 questionsYubo International Biotech Limited (YBGJ) reported revenue of $0.00B for 2025, up 3772.9% year-over-year.
YBGJ revenueYBGJ salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15